Navigation Links
Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response

Researchers have developed a vaccine strategy for head and neck cancer that targets multiple peptides (parts of proteins) to activate the immune system// to attack tumors.

The researchers created the vaccine to target a tumor suppressor gene called p53, which is mutated in most cancers and associated with poor clinical outcomes. Previous research has determined that mutated p53 also expresses unaltered, or "wild-type," p53 peptides in tumors. When presented on dendritic cells, these wild-type p53 peptides may induce an immune response to strengthen the body's natural defenses against cancer and decrease the chance of cancer recurrence and the formation of secondary tumors.

"The key to our strategy is to select those p53 peptides that can best activate the immune system and induce it to produce immune cells able to recognize and eliminate the tumor," said Theresa Whiteside, Ph.D., who in collaboration with Albert DeLeo, Ph.D., directed the study. Both investigators are professors of pathology and immunology at the University of Pittsburgh School of Medicine. "Through animal models and human cells in culture, we have found that this strategy is very effective at stimulating T cells into action," said Dr. Whiteside, who also directs UPCI's Immunologic Monitoring and Cellular Products Laboratory. According to Dr. DeLeo, the vaccine based on these findings also could be relevant to other types of cancer given that the loss of p53 function is a common feature across many cancers.

The vaccine is based on three peptides derived from p53 that target killer T cells and helper T cells. Although killer T cells directly destroy tumor cells, they are assisted by helper T cells that secrete small proteins called cytokines to regulate or "help" the immune response.

Given that the proof of principle for the vaccine has been determined, a phase I clinical trial of the vaccine has begun at the University of Pittsburgh Cancer Institut e to assess its safety in head and neck cancer patients.

Head and neck cancer accounts for about 5 percent of all newly diagnosed cancers in the United States. More than two-thirds of head and neck cancer patients have a locally advanced stage when diagnosed and have a poor five-year survival rate even after treatment.

Source-Eurekalert
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology: